CA2945574C - Process for producing targeted mutations in bacterial genomes with crispr/cas system - Google Patents
Process for producing targeted mutations in bacterial genomes with crispr/cas system Download PDFInfo
- Publication number
- CA2945574C CA2945574C CA2945574A CA2945574A CA2945574C CA 2945574 C CA2945574 C CA 2945574C CA 2945574 A CA2945574 A CA 2945574A CA 2945574 A CA2945574 A CA 2945574A CA 2945574 C CA2945574 C CA 2945574C
- Authority
- CA
- Canada
- Prior art keywords
- bacteria
- pam
- protospacer
- crispr
- imr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- 230000035772 mutation Effects 0.000 title claims abstract description 66
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 62
- 230000008569 process Effects 0.000 title claims abstract description 42
- 108091033409 CRISPR Proteins 0.000 title claims description 49
- 241000894006 Bacteria Species 0.000 claims abstract description 134
- 238000005215 recombination Methods 0.000 claims abstract description 81
- 230000006798 recombination Effects 0.000 claims abstract description 80
- 238000010453 CRISPR/Cas method Methods 0.000 claims abstract description 44
- 239000013598 vector Substances 0.000 claims description 95
- 238000006467 substitution reaction Methods 0.000 claims description 86
- 108020004414 DNA Proteins 0.000 claims description 54
- 238000010354 CRISPR gene editing Methods 0.000 claims description 45
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 125000006850 spacer group Chemical group 0.000 claims description 29
- 238000012217 deletion Methods 0.000 claims description 27
- 230000037430 deletion Effects 0.000 claims description 27
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 241001112696 Clostridia Species 0.000 claims description 14
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 12
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 241001508458 Clostridium saccharoperbutylacetonicum Species 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000002703 mutagenesis Methods 0.000 claims description 6
- 231100000350 mutagenesis Toxicity 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 230000034994 death Effects 0.000 claims description 5
- 241000193469 Clostridium pasteurianum Species 0.000 claims description 4
- 241000429427 Clostridium saccharobutylicum Species 0.000 claims description 4
- 241000193452 Clostridium tyrobutyricum Species 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 3
- 241000193401 Clostridium acetobutylicum Species 0.000 claims description 3
- 241001656809 Clostridium autoethanogenum Species 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 241000178335 Caldicellulosiruptor saccharolyticus Species 0.000 claims description 2
- 241000719667 Clostridium arbusti Species 0.000 claims description 2
- 241000186522 Clostridium aurantibutyricum Species 0.000 claims description 2
- 241000193454 Clostridium beijerinckii Species 0.000 claims description 2
- 241000193171 Clostridium butyricum Species 0.000 claims description 2
- 241000193169 Clostridium cellulovorans Species 0.000 claims description 2
- 241000272479 Clostridium diolis Species 0.000 claims description 2
- 241001509473 Clostridium homopropionicum Species 0.000 claims description 2
- 241000186570 Clostridium kluyveri Species 0.000 claims description 2
- 241000186566 Clostridium ljungdahlii Species 0.000 claims description 2
- 241001468167 Clostridium magnum Species 0.000 claims description 2
- 241000186581 Clostridium novyi Species 0.000 claims description 2
- 241001147704 Clostridium puniceum Species 0.000 claims description 2
- 241001656801 Clostridium roseum Species 0.000 claims description 2
- 241000186520 Clostridium tetanomorphum Species 0.000 claims description 2
- 241001147721 Clostridium thermobutyricum Species 0.000 claims description 2
- 241001147708 Clostridium thermopalmarium Species 0.000 claims description 2
- 241000193453 [Clostridium] cellulolyticum Species 0.000 claims description 2
- 241001656792 [Clostridium] thermosuccinogenes Species 0.000 claims description 2
- 241001430149 Clostridiaceae Species 0.000 claims 1
- 241000193448 Ruminiclostridium thermocellum Species 0.000 claims 1
- 230000009466 transformation Effects 0.000 abstract description 18
- 238000002744 homologous recombination Methods 0.000 abstract description 8
- 230000006801 homologous recombination Effects 0.000 abstract description 8
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 137
- 210000004027 cell Anatomy 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 25
- 108090000623 proteins and genes Proteins 0.000 description 23
- 241001112695 Clostridiales Species 0.000 description 18
- 241000242493 Clostridium saccharoperbutylacetonicum N1-4(HMT) Species 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000003550 marker Substances 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000013211 curve analysis Methods 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 101150044726 pyrE gene Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007480 sanger sequencing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 241000193464 Clostridium sp. Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003578 bacterial chromosome Anatomy 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AHLWZBVXSWOPPL-RGYGYFBISA-N 20-deoxy-20-oxophorbol 12-myristate 13-acetate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(C=O)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C AHLWZBVXSWOPPL-RGYGYFBISA-N 0.000 description 1
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000203809 Actinomycetales Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108091079001 CRISPR RNA Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 101100189168 Capsicum frutescens PAMT gene Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000382842 Flavobacterium psychrophilum Species 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 108091029499 Group II intron Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 241001602688 Pama Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002932 Thiolase Human genes 0.000 description 1
- 108060008225 Thiolase Proteins 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940015062 campylobacter jejuni Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 101150027417 recU gene Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001523 saccharolytic effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1406970.2A GB201406970D0 (en) | 2014-04-17 | 2014-04-17 | Targeted mutations |
| GB1406970.2 | 2014-04-17 | ||
| PCT/GB2015/051153 WO2015159087A1 (en) | 2014-04-17 | 2015-04-16 | Targeted mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2945574A1 CA2945574A1 (en) | 2015-10-22 |
| CA2945574C true CA2945574C (en) | 2022-10-25 |
Family
ID=50928941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2945574A Active CA2945574C (en) | 2014-04-17 | 2015-04-16 | Process for producing targeted mutations in bacterial genomes with crispr/cas system |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10508271B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3132036B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6621465B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102272684B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106460000B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016023814B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2945574C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3132036T3 (cg-RX-API-DMAC7.html) |
| GB (2) | GB201406970D0 (cg-RX-API-DMAC7.html) |
| MY (1) | MY176328A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015159087A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| WO2015066119A1 (en) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US9840699B2 (en) | 2013-12-12 | 2017-12-12 | President And Fellows Of Harvard College | Methods for nucleic acid editing |
| US10787654B2 (en) | 2014-01-24 | 2020-09-29 | North Carolina State University | Methods and compositions for sequence guiding Cas9 targeting |
| EP3690044B1 (en) | 2014-02-11 | 2024-01-10 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
| CN106460003A (zh) | 2014-04-08 | 2017-02-22 | 北卡罗来纳州立大学 | 用于使用crispr相关基因rna引导阻遏转录的方法和组合物 |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| EP3186375A4 (en) | 2014-08-28 | 2019-03-13 | North Carolina State University | Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING |
| EP3291679B1 (en) | 2015-05-06 | 2021-12-15 | SNIPR Technologies Limited | Altering microbial populations & modifying microbiota |
| HK1253712A1 (zh) | 2015-05-29 | 2019-06-28 | North Carolina State University | 使用crispr核酸筛选细菌、古细菌、藻类和酵母的方法 |
| CN107922918B (zh) | 2015-06-15 | 2022-10-21 | 北卡罗来纳州立大学 | 用于有效递送核酸和基于rna的抗微生物剂的方法和组合物 |
| EP3356533A1 (en) | 2015-09-28 | 2018-08-08 | North Carolina State University | Methods and compositions for sequence specific antimicrobials |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| WO2017112620A1 (en) | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
| CN108473986A (zh) * | 2016-01-08 | 2018-08-31 | 诺维信公司 | 芽孢杆菌宿主细胞的基因组编辑 |
| KR20180110144A (ko) | 2016-02-26 | 2018-10-08 | 란자테크 뉴질랜드 리미티드 | C1-고정 박테리아에 대한 crispr/cas 시스템 |
| WO2017190257A1 (en) * | 2016-05-01 | 2017-11-09 | Neemo Inc | Harnessing heterologous and endogenous crispr-cas machineries for efficient markerless genome editing in clostridium |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| AU2017280353B2 (en) | 2016-06-24 | 2021-11-11 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
| KR102827276B1 (ko) | 2016-08-03 | 2025-07-01 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CN111051510A (zh) * | 2017-06-25 | 2020-04-21 | 斯尼普技术有限公司 | 改变微生物群体和修饰微生物群 |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| GB201712733D0 (en) | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| GB201716845D0 (en) | 2017-10-13 | 2017-11-29 | Green Biologics Ltd | Process |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| KR102208031B1 (ko) * | 2018-08-20 | 2021-01-27 | 경상대학교산학협력단 | 표적 유전자의 활성산소종 매개 염기 돌연변이 유도 방법 |
| US12203123B2 (en) | 2018-10-01 | 2025-01-21 | North Carolina State University | Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells |
| US12264330B2 (en) | 2018-10-01 | 2025-04-01 | North Carolina State University | Recombinant type I CRISPR-Cas system and uses thereof for killing target cells |
| WO2020072250A1 (en) | 2018-10-01 | 2020-04-09 | North Carolina State University | Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression |
| EP3861120A4 (en) | 2018-10-01 | 2023-08-16 | North Carolina State University | Recombinant type i crispr-cas system |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US11142751B2 (en) | 2019-03-07 | 2021-10-12 | Auburn University | CRISPR-cas system for Clostridium genome engineering and recombinant strains produced thereof |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4136221A4 (en) * | 2020-04-15 | 2024-10-23 | University Of Alaska Anchorage | PROCESSES AND COMPOSITIONS FOR THE PRODUCTION OF ISOBUTENE |
| WO2021211972A1 (en) * | 2020-04-16 | 2021-10-21 | Zymergen Inc. | Circular-permuted nucleic acids for homology-directed editing |
| AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| EP4165178A4 (en) * | 2020-06-10 | 2024-06-19 | North Carolina State University | NOVEL TYPE I CRISPR-CAS SYSTEM FROM CLOSTRIDIA |
| CN112029699B (zh) * | 2020-11-04 | 2021-06-08 | 中国农业科学院北京畜牧兽医研究所 | 一种基于内源CRISPR-Cas系统的丁酸梭菌基因编辑系统及其应用 |
| EP4230721A1 (en) * | 2022-02-17 | 2023-08-23 | Evonik Operations GmbH | Microorganisms with reduced competence |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO323345B1 (no) | 2002-01-07 | 2007-04-02 | Norwegian Inst Of Fisheries An | Forbedring av fiskeprodukter og fôr |
| GB0612301D0 (en) | 2006-06-21 | 2006-08-02 | Morvus Technology Ltd | DNA molecules and methods |
| CN101528930B (zh) | 2006-10-03 | 2013-12-11 | 代谢探索者公司 | 用于在梭菌属中进行染色体整合和dna序列替换的方法 |
| US20110119779A1 (en) | 2007-12-10 | 2011-05-19 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
| GB0802842D0 (en) | 2008-02-15 | 2008-03-26 | Univ Nottingham | Synthetic operon construction in clostridia |
| WO2009137778A2 (en) | 2008-05-08 | 2009-11-12 | Northwestern University | Methods and compositions for genetically engineering clostridia species |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2010127111A1 (en) | 2009-04-30 | 2010-11-04 | The Trustees Of Comlumbia University In The City Of New York | In vivo assembly of dna via homologous recombination |
| WO2013133882A2 (en) | 2011-12-16 | 2013-09-12 | University Of Delaware | Recombinant clostridium organism and method for isolation of double-crossover allelic exchange mutants |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| WO2014143381A1 (en) | 2013-03-09 | 2014-09-18 | Agilent Technologies, Inc. | Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events |
| AU2014273082B2 (en) * | 2013-05-29 | 2018-11-08 | Cellectis | A method for producing precise DNA cleavage using Cas9 nickase activity |
| DE202014010413U1 (de) | 2013-09-18 | 2015-12-08 | Kymab Limited | Zellen und Organismen |
| EP3690044B1 (en) | 2014-02-11 | 2024-01-10 | The Regents of the University of Colorado, a body corporate | Crispr enabled multiplexed genome engineering |
-
2014
- 2014-04-17 GB GBGB1406970.2A patent/GB201406970D0/en not_active Ceased
-
2015
- 2015-04-16 KR KR1020167032080A patent/KR102272684B1/ko not_active Expired - Fee Related
- 2015-04-16 CN CN201580024688.XA patent/CN106460000B/zh not_active Expired - Fee Related
- 2015-04-16 GB GB1506460.3A patent/GB2530831B/en active Active
- 2015-04-16 DK DK15718988.7T patent/DK3132036T3/da active
- 2015-04-16 MY MYPI2016703657A patent/MY176328A/en unknown
- 2015-04-16 BR BR112016023814-1A patent/BR112016023814B1/pt not_active IP Right Cessation
- 2015-04-16 JP JP2017505733A patent/JP6621465B2/ja not_active Expired - Fee Related
- 2015-04-16 CA CA2945574A patent/CA2945574C/en active Active
- 2015-04-16 US US15/304,483 patent/US10508271B2/en active Active
- 2015-04-16 EP EP15718988.7A patent/EP3132036B8/en active Active
- 2015-04-16 WO PCT/GB2015/051153 patent/WO2015159087A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| GB201406970D0 (en) | 2014-06-04 |
| GB201506460D0 (en) | 2015-06-03 |
| WO2015159087A1 (en) | 2015-10-22 |
| CN106460000A (zh) | 2017-02-22 |
| DK3132036T3 (da) | 2020-03-16 |
| GB2530831A (en) | 2016-04-06 |
| BR112016023814B1 (pt) | 2023-02-07 |
| CA2945574A1 (en) | 2015-10-22 |
| US10508271B2 (en) | 2019-12-17 |
| GB2530831B (en) | 2016-11-30 |
| BR112016023814A2 (pt) | 2017-10-17 |
| US20170037393A1 (en) | 2017-02-09 |
| CN106460000B (zh) | 2019-12-27 |
| KR102272684B1 (ko) | 2021-07-02 |
| MY176328A (en) | 2020-07-29 |
| EP3132036A1 (en) | 2017-02-22 |
| JP2017511156A (ja) | 2017-04-20 |
| EP3132036B1 (en) | 2020-01-15 |
| JP6621465B2 (ja) | 2019-12-18 |
| EP3132036B8 (en) | 2020-04-22 |
| KR20160147844A (ko) | 2016-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2945574C (en) | Process for producing targeted mutations in bacterial genomes with crispr/cas system | |
| US10550396B2 (en) | Deletion mutations | |
| US20240002835A1 (en) | Genetic tool for the transformation of clostridium bacteria | |
| Zhang et al. | Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production | |
| US11946067B2 (en) | Optimized genetic tool for modifying Clostridium bacteria | |
| AU2017260714B2 (en) | Harnessing heterologous and endogenous CRISPR-Cas machineries for efficient markerless genome editing in clostridium | |
| Jiang et al. | Highly efficient genome editing in Xanthomonas oryzae pv. oryzae through repurposing the endogenous type I‐C CRISPR‐Cas system | |
| JP7555599B2 (ja) | 遺伝子的に改変されたｃｌｏｓｔｒｉｄｉｕｍ細菌の、調製およびその使用。 | |
| Little et al. | The butanol producing microbe Clostridium beijerinckii NCIMB 14988 manipulated using forward and reverse genetic tools | |
| US12385023B2 (en) | CRISPR-Cas system for clostridium genome engineering and recombinant strains produced thereof | |
| US12473527B2 (en) | Optimized genetic tool for modifying bacteria | |
| KR101647143B1 (ko) | 클로스트리듐 속 미생물 유전자를 불활성화시키는 방법 | |
| Bengelsdorf et al. | Host organisms: Clostridium acetobutylicum/Clostridium beijerinckii and related organisms | |
| Zhang | butanol production, Metabolic Engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200414 |
|
| EEER | Examination request |
Effective date: 20200414 |
|
| EEER | Examination request |
Effective date: 20200414 |